{"entity":{"id":"mrc-ctu","kind":"company","name":"MRC Clinical Trials Unit at UCL","aka":["Medical Research Council","MRC","MRC CTU","MRC CTU at UCL","UCL Innovative Clinical Trials Unit","MRC Clinical Trials Unit"],"tldr":"The MRC Clinical Trials Unit at UCL is the UK public trials unit that designed and ran STAMPEDE, FOCUS4, ICON7 and UKCTOCS; it marked 25 years in 2024 and became the UCL Innovative Clinical Trials Unit in April 2026.","summary":"The MRC Clinical Trials Unit at UCL is a registered clinical trials unit (UKCRC Registered CTUs Network) at 90 High Holborn, London, that designs and conducts clinical trials, systematic reviews and observational studies; its website records a 25th anniversary in 2024 and says the unit became the UCL Innovative Clinical Trials Unit in April 2026, continuing the same mission. No founding year is stated on the pages read, so none is given here. ClinicalTrials.gov names the Medical Research Council (OTHER_GOV class) as lead sponsor of STAMPEDE (NCT00268476, the multi-arm platform trial in advanced prostate cancer); FOCUS4 (ISRCTN90061546, the biomarker-stratified colorectal cancer platform) is recorded in OnCo as run by the unit with Medical Research Council, NIHR and Cancer Research UK funding; ICON7 (recorded with GOG-0218, bevacizumab in ovarian cancer) and UKCTOCS (NCT00058032, ovarian cancer screening, registered by University College London with the Medical Research Council as collaborator) are its other OnCo trials. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"MRC CTU at UCL: about us","url":"https://www.mrcctu.ucl.ac.uk/about-us/"},{"label":"ClinicalTrials.gov: trials led by Medical Research Council","url":"https://clinicaltrials.gov/search?lead=Medical%20Research%20Council"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["prostate","prostate-mhspc","prostate-high-risk","colorectal","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":["stampede","focus4","gog-0218-icon7","ukctocs"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"London","country":"GB","companyType":"cooperative-group","website":"https://www.mrcctu.ucl.ac.uk","investors":[],"funding":[]},"route":"/companies/mrc-ctu/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/"},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"institution":[{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/"}],"trial":[{"id":"focus4","kind":"trial","name":"FOCUS4","route":"/trials/focus4/"},{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/"},{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/"},{"id":"ukctocs","kind":"trial","name":"UKCTOCS","route":"/trials/ukctocs/"}]}}